Clinical trials: GLP-1
Polycystic Ovary Syndrome, Obesity
Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age and one of the leading causes of infertility.
- Conditions
- Polycystic Ovary Syndrome, Obesity, Infertility, Female
- Trial name
- NCT05952882
- Testing
- Liraglutide + Metformin, Metformin
- Volunteers
- 188 people
- Sponsor
- Mỹ Đức Hospital
Congestive Heart Failure, Type 2 Diabetes Mellitus
Liraglutide and Heart Failure in Type 2 Diabetes
Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin with insulinotropic properties. Apart from the glycemic actions, cardiovascular effects by GLP-1 have recently been reviewed.
- Trial name
- NCT01425580
- Testing
- liraglutide, glimepiride, Metformin
- Where
- 2 sites in Sweden
- Volunteers
- 62 people
- Sponsor
- Thomas Nystrom
Type 1 Diabetes, Hypoglycemia
Dual-hormone Closed-loop Glucose Control in Type 1 Diabetes
Despite recent pharmacological and technological advantages, hypoglycemia remains to be the key limiting factor in achieving optimal glycemic control in people with type 1 diabetes.
- Trial name
- DHCL2019 (NCT04053712)
- Testing
- Glucagon, Closed-loop system
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Steno Diabetes Center Copenhagen
Gastroparesis, Functional Dyspepsia
Effects of Liraglutide on Body Surface Gastric Mapping
Aim 1: To investigate, in healthy participants, the effect of liraglutide injection on gastric electrophysiology (as measured by body surface gastric mapping using the Gastric Alimetry device) during an 13-dayramping dose of…
- Conditions
- Gastroparesis, Functional Dyspepsia, Chronic Nausea and Vomiting Syndrome, Healthy
- Trial name
- NCT06500130
- Testing
- Body Surface Gastric Mapping
- Where
- New Zealand
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Alimetry
Cardiometabolic Conditions
Effects of N-Acyl Taurines on Incretin Levels in Healthy Subjects
This study is an investigator-initiated, randomised, double-blind, placebo-controlled, cross-over human trial investigating the effect of arachidonoyl-taurine (C20:4-taurine) and oleoyl-taurine (C18:1-taurine) on GLP-1 secretion…
- Trial name
- NAT-INC (NCT07771166)
- Testing
- Arachidonoyl-taurine: First dose at 0 hours, Oleoyl-taurine: First dose at 0 hours, Liquid meal and second dose of OLE-T at 3 hours
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Obesity
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide.
- Trial name
- NCT05671653
- Testing
- PF-07081532, Semaglutide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy
This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study. The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients who are currently on…
- Trial name
- NCT00674466
- Testing
- 1.5 mg or 2.0 mg CJC-1134-PC
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- ConjuChem
Pneumonia, Aspiration, Anesthesia
Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study
Medicines with peptide-1 receptor agonist action similar to glucagon (GLP-1) are a modern therapeutic option for obesity and diabetes mellitus.
- Trial name
- NCT06154486
- Testing
- semaglutide use
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Hospital Israelita Albert Einstein
Type 2 Diabetes
GLP-1 REceptor Agonists and Real World EvIdeNce
Glucagon-like peptide-1 receptor agonists (GLP-1RA) are powerful second-line agents for the treatment of type 2 diabetes. GLP-1RA have bene marketed in 2010 in Italy and years of experience have accumulated for the treatment with…
- Trial name
- GLP-1REWIN (NCT03959865)
- Testing
- Long-acting GLP-1RA, Short-acting GLP-1RA, Human-based GLP-1RA
- Where
- 6 sites in Italy
- Volunteers
- 6,000 people
- Sponsor
- University of Padova
Psoriasis (PsO), Obesity & Overweight
Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis
This study will evaluate the effects of oral semaglutide in combination with topical corticosteroid/calcipotriol on clinical outcomes and metabolic inflammation in patients with plaque psoriasis and overweight/obesity and/or type…
- Conditions
- Psoriasis (PsO), Obesity & Overweight, Diabetes Mellitus - Type 2
- Trial name
- SEMAPSO (NCT07401992)
- Testing
- Semaglutide (Rybelsus®)
- Where
- Mexico
- Volunteers
- 62 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Hypoglycemia, Hypoglycemia, Reactive
Post-Prandial Carbohydrate Metabolism in Individuals With and Without Post-Bariatric Surgery Hypoglycemia (PBH)
In this study, the investigators will determine (a) whether metabolism (secretion and turnover) of glucagon is altered in patients with PBH, (b) whether this is affected by a meal, (c) whether PBH affects the ability of the body…
- Conditions
- Hypoglycemia, Hypoglycemia, Reactive, Bariatric Surgery
- Trial name
- NCT07818707
- Testing
- Glucagon for Injection (Fresenius Kabi USA), [6,6-2H2] glucose, [13C9, 15N1]-glucagon
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Joslin Diabetes Center
Kidney Functional
GLP-1: Acute Effects on Kidney Function in Healthy Men
The purpose of this study is to investigate how Glucagon-Like Peptide 1 (GLP-1) affects kidney function in healthy young men. The hypothesis is that GLP-1 induces a positive effect on kidney hemodynamics.
- Trial name
- NCT01333163
- Testing
- Human GLP-1 (7-36) amide, Isotone NaCl
- Where
- Denmark
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jeppe Skov
Eating Behavior
Effect of Food Acceptability on Appetite Hormones' Response in Normal Weight vs. Obese Male Subjects
Male subjects with specific body characteristics were recruited for the study. Subjects did an acceptability test on custard and completed a screening questionnaire.
- Trial name
- NCT03779321
- Testing
- Acceptability
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- American University of Beirut Medical Center
Metabolic Dysfunction-Associated Steatotic Liver Disease
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease…
- Trial name
- NCT07165028
- Testing
- Tirzepatide, Retatrutide
- Where
- 563 sites in United States, Argentina and 32 more
- Volunteers
- 4,500 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus
The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 (dulaglutide) in participants with type 2 diabetes mellitus taking an oral antihyperglycemic medication (OAM).
- Trial name
- NCT01584232
- Testing
- LY2189265, Insulin glargine, Sulfonylureas (SU)
- Where
- 15 sites in Japan
- Volunteers
- 361 people
- Sponsor
- Eli Lilly and Company
Obesity, Weight Change Trajectory
Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide
Fractyl is evaluating Revita Duodenal Mucosal Resurfacing (DMR) in the REMAIN-1 pivotal study, which is designed to include two cohorts - an open label cohort referred to as REVEAL-1, and a randomized cohort, which includes both…
- Conditions
- Obesity, Weight Change Trajectory, Weight Change, Body
- Trial name
- REMAIN-1 (NCT06484114)
- Testing
- Revita Duodenal Mucosal Resurfacing (DMR)
- Where
- 32 sites in United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Fractyl Health Inc.
Heart Failure With Preserved Ejection Fraction, Obesity
GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry
GLIDE-HF is a prospective, single-center, non-interventional observational cohort registry conducted within routine outpatient heart failure care at a cardiology clinic in Poland.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Obesity, Diastolic Heart Failure, Pulmonary Hypertension
- Trial name
- GLIDE-HF (NCT07787936)
- Testing
- GLP-1 / GIP receptor agonist
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- Miedziowe Centrum Zdrowia SA
Addiction, Alcohol Use Disorder
Semaglutide Therapy for Alcohol Reduction (STAR)
Background: Alcohol use disorder (AUD) is a problematic pattern of alcohol use accompanied by clinically significant medical consequences.
- Trial name
- NCT06015893
- Testing
- Take Control, Semaglutide
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Congenital Hyperinsulinism
Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia
The primary aim of this study is to evaluate the effect of Exendin (9-39) on glucose requirements to maintain euglycemia in pediatric patients with congenital hyperinsulinism (CHI) who have failed medical therapy.
- Trial name
- NCT00835328
- Testing
- Exendin (9-39), Vehicle
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Diva De Leon
Cerebral Small Vessel Disease
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
Cerebral small vessel disease (cSVD), a result of neurovascular cell dysfunction, is a major cause of stroke, dementia and mobility problems worldwide.
- Trial name
- GAPP-SVD (NCT05356104)
- Testing
- GLP-1 receptor agonist
- Where
- 2 sites in China, Hong Kong
- Volunteers
- 110 people
- Sponsor
- Chinese University of Hong Kong